Home › Asset managers › Blackstone Alternative Investment Funds › 2025-2026 › Against the board
Two kinds of vote are listed: a board-sponsored proposal Blackstone Alternative Investment Funds voted AGAINST or withheld on, and a shareholder proposal it voted FOR, with the board’s recommendation on it where the filings show one. A FOR vote on a proposal the board supported, or took no position on, is listed and labelled, but it is not a vote against the board. One row is one proposal at one meeting; “funds” is how many of the manager’s funds or accounts voted that way.
Everything Only shareholder proposals it backed
1,352 proposals.
| Company | Meeting | Proposal | Category | On the ballot from | Board recommended | Blackstone Alternative Investment Funds voted | Funds |
|---|---|---|---|---|---|---|---|
| Wealthfront Corporation | 2026-06-23 | Election of Class I Directors: Andrew S. Rachleff | Director Elections | Board | WITHHOLD | 1 | |
| Wealthfront Corporation | 2026-06-23 | Election of Class I Directors: David Fortunato | Director Elections | Board | WITHHOLD | 1 | |
| Weis Markets, Inc. | 2026-04-30 | Election of Directors: Harold G. Graber | Director Elections | Board | WITHHOLD | 1 | |
| Weis Markets, Inc. | 2026-04-30 | Election of Directors: Jonathan H. Weis | Director Elections | Board | WITHHOLD | 1 | |
| Wesbanco, Inc. | 2026-04-15 | To approve an advisory (non-binding) vote on compensation paid to Wesbanco's named executive officers in 2025. | Say-on-Pay | Board | AGAINST | 1 | |
| Westwater Resources, Inc. | 2026-05-22 | Approve an amendment to the 2013 Omnibus Incentive Plan, as amended, to increase the authorized number of shares of common stock available and reserved for issuance under the Incentive Plan by 6.1 million shares. | Compensation | Board | AGAINST | 1 | |
| Willis Lease Finance Corporation | 2026-06-23 | Cast an advisory vote to approve the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | Say-on-Pay | Board | AGAINST | 1 | |
| Willis Lease Finance Corporation | 2026-06-23 | Elect one Class I Director to serve until the 2029 Annual Meeting of Stockholders, specifically and as nominated by the Board of Directors: Stephen Jones | Director Elections | Board | WITHHOLD | 1 | |
| Windtree Therapeutics, Inc. | 2025-08-28 | To approve an amendment of the Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio of no less than 1-for-2 and not greater than 1-for-25, with the exact ratio within such range and the timing of such reverse stock split to be determined at the sole discretion of our board of directors, or the Board; and | Capital Structure | Board | AGAINST | 1 | |
| Windtree Therapeutics, Inc. | 2025-08-28 | To approve the issuance of shares of common stock, or the ELOC Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), pursuant to that certain Common Stock Purchase Agreement, or the ELOC Purchase Agreement, establishing an equity line of credit; | Capital Structure | Board | AGAINST | 1 | |
| Windtree Therapeutics, Inc. | 2025-08-28 | To approve the issuance of shares of common stock, or the Series E Warrant Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the exercise of common stock purchase warrants, or the Series E Warrants, with an initial exercise price of $0.75; | Capital Structure | Board | AGAINST | 1 | |
| Windtree Therapeutics, Inc. | 2025-08-28 | To approve the issuance of the maximum number of shares of common stock, or the Series E Convertible Shares, in accordance with Nasdaq Listing Rules 5635(b) and (d), upon the conversion of our Series E Convertible Preferred Stock, par value $0.001 per share, or Series E Preferred Stock, at an initial conversion price of $0.30; | Capital Structure | Board | AGAINST | 1 | |
| Workhorse Group Inc. | 2026-06-29 | Approve the Amended and Restated Workhorse Group 2023 Long-Term Incentive Plan. | Compensation | Board | AGAINST | 1 | |
| Workhorse Group Inc. | 2026-06-29 | Election of Directors: Matthew O'Leary | Director Elections | Board | AGAINST | 1 | |
| Workhorse Group Inc. | 2026-06-29 | Election of Directors: Paul Savoie | Director Elections | Board | AGAINST | 1 | |
| Workiva Inc. | 2026-05-28 | Approval of the Amendment and Restatement of the Workiva Inc. 2014 Equity Incentive Plan to increase the number of shares that may be issued under the Plan. | Compensation | Board | AGAINST | 1 | |
| Workiva Inc. | 2026-05-28 | Election of Directors: Michael M. Crow, Ph.D. | Director Elections | Board | WITHHOLD | 1 | |
| XPLR Infrastructure, LP | 2026-05-06 | Election as directors of the nominees specified in the proxy statement: John W. Ketchum | Director Elections | Board | AGAINST | 1 | |
| Xencor, Inc. | 2026-06-16 | Approval of the amendment to the Company's Amended and Restated 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 4,000,000 shares; and | Compensation | Board | AGAINST | 1 | |
| Xenon Pharmaceuticals Inc. | 2026-06-02 | To approve the Corporation's 2026 Equity Incentive Plan; | Compensation | Board | AGAINST | 1 | |
| Xeris Biopharma Holdings, Inc. | 2026-06-04 | To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Dawn Halkuff | Director Elections | Board | WITHHOLD | 1 | |
| Xerox Holdings Corporation | 2026-05-20 | Approve an amendment to the Xerox Holdings Corporation 2024 Equity and Performance Incentive Plan to increase the share reserve. | Compensation | Board | AGAINST | 1 | |
| Xilio Therapeutics, Inc. | 2025-11-21 | To approve a one-time repricing of certain outstanding employee stock options. | Compensation | Board | AGAINST | 1 | |
| Xilio Therapeutics, Inc. | 2025-11-21 | To approve the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan. | Compensation | Board | AGAINST | 1 | |
| Xos, Inc. | 2026-06-23 | To approve the 2026 Amendment to the Xos, Inc. Amended and Restated 2021 Equity Incentive Plan. | Compensation | Board | AGAINST | 1 | |
| Xos, Inc. | 2026-06-23 | To approve, on a non-binding advisory basis, the fiscal year 2025 compensation of the Company's named executive officers. | Say-on-Pay | Board | AGAINST | 1 | |
| Xos, Inc. | 2026-06-23 | To elect three Class II directors to each serve for a three-year term ending at the Company's 2029 annual meeting or until his or her successor is duly elected and qualified: George N. Mattson | Director Elections | Board | WITHHOLD | 1 | |
| Y-mAbs Therapeutics, Inc. | 2025-07-11 | Election of Class I Director: David N. Gill | Director Elections | Board | WITHHOLD | 1 | |
| Zai Lab Limited | 2026-06-17 | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. | Say-on-Pay | Board | AGAINST | 1 | |
| Zenas BioPharma, Inc. | 2026-05-11 | To elect the two Class II director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: James Boylan | Director Elections | Board | AGAINST | 1 | |
| Zentalis Pharmaceuticals, Inc. | 2026-06-16 | Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | Say-on-Pay | Board | AGAINST | 1 | |
| Zentalis Pharmaceuticals, Inc. | 2026-06-16 | Election of each of the Class III Directors to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: David Johnson | Director Elections | Board | WITHHOLD | 1 | |
| Zevia PBC | 2026-06-10 | Election of Directors: To be elected for terms expiring in 2029: David J. Lee | Director Elections | Board | AGAINST | 1 | |
| Zhihu Inc. | 2026-06-30 | Adopt Amended and Restated 2022 Share Incentive Plan | Compensation | Board | AGAINST | 1 | |
| Zhihu Inc. | 2026-06-30 | Adopt Service Provider Sublimit | Compensation | Board | AGAINST | 1 | |
| Zhihu Inc. | 2026-06-30 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights | Capital Structure | Board | AGAINST | 1 | |
| Zhihu Inc. | 2026-06-30 | Approve PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as Auditors and Authorize Board to Fix Their Remuneration | Audit-related | Board | AGAINST | 1 | |
| Zhihu Inc. | 2026-06-30 | Authorize Reissuance of Repurchased Shares | Capital Structure | Board | AGAINST | 1 | |
| ZipRecruiter, Inc. | 2026-06-09 | Election of Class II Directors for three-year term: Brie Carere | Director Elections | Board | WITHHOLD | 1 | |
| ZoomInfo Technologies Inc. | 2026-05-14 | To approve, on an advisory, non-binding basis, the compensation of our named executive officers. | Say-on-Pay | Board | AGAINST | 1 | |
| ZoomInfo Technologies Inc. | 2026-05-14 | To elect the director nominees listed in the Proxy Statement: Katie Rooney | Director Elections | Board | WITHHOLD | 1 | |
| Zscaler, Inc. | 2026-01-12 | To elect three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected and qualified, subject to their earlier death, resignation or removal: Andrew Brown | Director Elections | Board | WITHHOLD | 1 | |
| Zura Bio Limited | 2026-06-17 | Amendment and Restatement of 2023 Zura Bio Limited Equity Incentive Plan: To approve, by ordinary resolution, the Amended and Restated 2023 Zura Bio Limited Equity Incentive Plan. | Compensation | Board | AGAINST | 1 | |
| aTyr Pharma, Inc. | 2026-05-11 | To approve an amendment to the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan, as amended; | Compensation | Board | AGAINST | 1 | |
| adidas AG | 2026-05-07 | Approve Management Board Remuneration Policy | Compensation | Board | AGAINST | 1 | |
| adidas AG | 2026-05-07 | Reelect Nassef Sawiris to the Supervisory Board | Director Elections | Board | AGAINST | 1 | |
| agilon health, inc. | 2026-06-02 | Election of Class II Directors: Karen McLoughlin | Director Elections | Board | AGAINST | 1 | |
| iHeartMedia, Inc. | 2026-06-04 | The approval, on an advisory (non-binding) basis, of the compensation of our named executive officers. | Say-on-Pay | Board | AGAINST | 1 | |
| iSpecimen Inc. | 2025-10-30 | To approve an amendment to certain outstanding convertible securities of the Company to increase the conversion price floor from 50% to 80% of the lowest volume weighted average price (VWAP) during the applicable measurement period, which may reduce the number of shares issuable upon conversion of such securities; | Capital Structure | Board | AGAINST | 1 | |
| iSpecimen Inc. | 2025-10-30 | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the Company's entry into an equity line of credit arrangement, and the potential issuance of shares of common stock pursuant to such arrangement, which may exceed 19.99% of the Company's outstanding common stock or voting power, at a price that may be below the Minimum Price (as defined in Nasdaq rules); and | Capital Structure | Board | AGAINST | 1 | |
| iSpecimen Inc. | 2025-10-30 | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of shares of common stock (or securities convertible into or exercisable for common stock), in one or more non-public financing transactions, in an aggregate amount exceeding 19.99% of the Company's outstanding common stock or voting power, at a price that may be below the Minimum Price (as defined in Nasdaq rules); | Capital Structure | Board | AGAINST | 1 | |
| iSpecimen Inc. | 2026-05-29 | To Approve the iSpecimen Inc. 2025 Stock Incentive Plan. | Compensation | Board | AGAINST | 1 |
← Previous Page 14 of 14
← Back to Blackstone Alternative Investment Funds 2025-2026 overview
Built 2026-10-12 from SEC Form N-PX filings.